Doxorubicin in combination with fluorouracil and cyclophosphamide (i.v. FAC regimen, day 1, 21) versus methotrexate in combination with fluorouracil and cyclophosphamide (i.v. CMF regimen, day 1, 21) as adjuvant chemotherapy for operable breast cancer: a study by the GEICAM group. [electronic resource]
Producer: 20031218Description: 833-42 p. digitalISSN:- 0923-7534
- Adolescent
- Adult
- Aged
- Antineoplastic Combined Chemotherapy Protocols -- adverse effects
- Breast Neoplasms -- drug therapy
- Chemotherapy, Adjuvant
- Cyclophosphamide -- adverse effects
- Disease-Free Survival
- Dose-Response Relationship, Drug
- Doxorubicin -- adverse effects
- Female
- Fluorouracil -- adverse effects
- Humans
- Infusions, Intravenous
- Lymphatic Metastasis
- Methotrexate -- adverse effects
- Middle Aged
- Neoplasm Staging
- Neoplasms, Hormone-Dependent -- drug therapy
- Prospective Studies
- Survival Rate
- Treatment Outcome
No physical items for this record
Publication Type: Clinical Trial; Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Review
There are no comments on this title.
Log in to your account to post a comment.